PHARMACY

L.A. Times: USC pilot program illustrates importance of clinical pharmacists

BY Antoinette Alexander

LOS ANGELES — A University of Southern California pilot currently underway at several clinics belonging to nonprofit clinic AltaMed is illustrating the important role that pharmacists can play in improving patient outcomes and easing the burden of the nation’s shortage of primary care physicians, according to a Los Angeles Times article.

The initiative, run by USC clinical pharmacy professor Steven Chen, is currently running at 10 clinics belonging to AltaMed, which serves largely low-income populations in Los Angeles and Orange counties, according to the article.

With team-based medical care as a central feature of the Affordable Care Act, the pilot is proving effective as, according to the article, the clinical pharmacists in the USC program are finding, on average, 10 drug-related problems per patient and are also acting much like a medical counselor.

The clinical pharmacists are paired with patients suffering from chronic illnesses and they typically see their patients once a month. Plus, each visits is typically longer — lasting up to an hour.

According to the LA Times report, early data from the pilot shows that clinical pharmacists can help lower overall healthcare costs by reducing hospitalizations and other costly medical treatments. This is critical as today’s payment models under the Affordable Care Act are shifting to penalize providers if patients do not stay healthy.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Diplomat Pharmacy celebrates four decades

BY Michael Johnsen

 
 
FLINT, Mich. – Diplomat Pharmacy is celebrating 40 years of providing quality pharmacy services to its patients nationwide, the company announced Friday.
 
Diplomat, founded in 1975 by Dale Hagerman and son Phil Hagerman, its current chairman and CEO, has grown into the nation’s largest independent specialty pharmacy. Founded on the philosophy “take good care of patients, and the rest falls into place,” Diplomat is committed to helping patients with complex chronic conditions.
 
Today, Diplomat relies on its history of innovation to set the standard for patient care. What started as a small, regional operation has since led to a national enterprise focused on customized solutions for each patient’s individual needs. At the root of the company’s expansion is the desire to help more patients find health. “We remain committed to our philosophy by taking care of one patient at a time for happier lives and health that lasts,” Phil Hagerman said.
 
“Our patients are more than customers; they are remarkable stories of human triumph. It is our honor to support their health, helping them thrive in their lives,” Hagerman added. “Our philosophy continues to be as it was when my dad had the pharmacy almost 40 years ago and we look forward to upholding for the next 40 years to come.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Test that identifies Strep A within eight minutes cleared by FDA

BY Michael Johnsen

WALTHAM, Mass. – Alere on Thursday announced that its Alere i Strep A test has received marketing clearance from the Food and Drug Administration. Alere i Strep A is the first molecular test that detects Group A Streptococcus (GAS) bacteria in throat swab specimens in 8 minutes or less.
 
Upon receipt of this clearance from the FDA, Alere submitted an application for CLIA (Clinical Laboratory Improvement Amendments) waiver of the Alere i Strep A test. Other assays currently in development on the Alere i platform include respiratory syncytial virus (RSV), C. difficile and Chlamydia/Gonorrhoea.
 
"This FDA clearance brings the power of our Alere i molecular platform to the detection of Strep A," stated Avi Pelossof, global president infectious diseases at Alere. "The speed and accuracy of the Alere i Strep A test empower healthcare professionals to initiate the right treatment in an actionable timeframe, which is a critical step in reducing unnecessary prescription of antibiotics and enhancing operational efficiency."
 
The Alere i molecular platform was initially cleared for marketing by the FDA for the detection and differentiation of influenza A and B virus in June 2014. In January 2015, Alere i Influenza A & B became the first-ever molecular test to receive CLIA waiver, which allows for broad use by healthcare providers, ranging from hospitals and physician offices to clinics and other healthcare settings. Expanding the menu on the Alere i platform to include Strep A and potentially other assays increases the utility of the platform for a wider range of users. Furthermore, given the less seasonal nature of Strep A, its addition enhances the value of the platform for users on a year-round basis.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES